A Multiple Drug Interaction Study of Stavudine with Agents for Opportunistic Infections in Human Immunodeficiency Virus-Infected Patients
AUTOR(ES)
Piscitelli, Stephen C.
FONTE
American Society for Microbiology
RESUMO
The effects of multiple opportunistic infection medications on stavudine pharmacokinetics were evaluated. Ten patients with CD4 counts of less than 200 cells/mm3 received stavudine (40 mg twice daily) in combination with one to three other drugs used to treat opportunistic infections. Serial blood samples for stavudine concentrations were collected after 1 week of therapy on each regimen and assayed for stavudine by using a validated high-pressure liquid chromatography method. Although the maximum concentration of drug in serum was significantly decreased when the drug was given in combination with three opportunistic infection medications, the area under the concentration-time curve did not significantly differ across various treatment regimens. Stavudine exposure was not significantly altered by multiple concomitant medications. Side effects were minor throughout the 3-month study period. The tolerability of stavudine, combined with its lack of drug interactions, makes it an attractive agent for use as part of a combination regimen.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89174Documentos Relacionados
- Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.
- Inflammatory Responses in Blood Samples of Human Immunodeficiency Virus-Infected Patients with Pulmonary Infections
- Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus.
- Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.
- Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects.
